#United States #New York #Class Action #Securities Law #INOVIO Pharmaceuticals

Inovio Pharmaceuticals Faces Class Action Lawsuit

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) is currently embroiled in a significant class action lawsuit concerning violations of securities law. The Gross Law Firm has issued an urgent notice to shareholders, urging those who acquired shares of Inovio during the specified class period to reach out and discuss their possible rights and next steps. The lawsuit could have vast implications for investors, particularly those who purchased shares between October 10, 2023, and December 26, 2025.

What Are the Allegations?

The complaint against Inovio alleges a series of misleading statements and omissions that may have inflated the stock's perceived value. Most notably, it claims that the company had serious deficiencies in the manufacturing process of its CELLECTRA device, which is critical for delivering the company's lead product candidate, INO-3107. As a result of these deficiencies, it is suggested that Inovio is unlikely to submit a Biologics License Application (BLA) for INO-3107 to the FDA by the anticipated deadline in the latter half of 2024.

The allegations further state that there wasn't sufficient data to support INO-3107's eligibility for fast-tracked FDA approval, leading to overstated regulatory and commercial prospects. This situation raises substantial concerns for investors who may have relied on the company's public statements while making investment decisions.

Why It's Important for Investors

For shareholders of Inovio Pharmaceuticals, this class action lawsuit represents more than just legal proceedings; it’s a potential pathway to recovery for investors who feel they were misled. The Gross Law Firm highlights that potential lead plaintiffs can register to be a part of the case without needing to incur costs or obligations. This is a crucial opportunity for investors to protect their rights and recover losses attributed to the alleged fraudulent activities.

The deadline to seek lead plaintiff status is April 7, 2026, and those interested are encouraged to take immediate action. Registration will not only enroll them in the proceedings but also provide continual updates regarding the lawsuit's status through advanced portfolio monitoring software.

Next Steps for Shareholders

Shareholders who find themselves included in the relevant class period are strongly advised to register their information promptly at the designated website for The Gross Law Firm. By doing so, they can ensure they are kept informed on the case's developments, potential settlements, and other critical information that may affect their investment.

Inovio Pharmaceuticals is under scrutiny for its actions, and the severity of the allegations signifies a shared responsibility for the company to uphold ethical standards in business practices. As the case unfolds, it places additional pressure on the corporation to maintain transparency and accountability to its investors.

Why Choose The Gross Law Firm?

The Gross Law Firm has established itself as a leader in class action lawsuits, advocating for investor rights against entities accused of deceptive practices. Their commitment to investor protection strives to ensure that corporations are held responsible for misleading tactics that result in financial losses. Attorney advertising has underscored that prior results do not guarantee the same outcomes, but the firm’s active engagement helps victims of corporate fraud seek justice and recovery.

For any investors affected by this situation, taking timely action is essential. Whether you are considering joining the lawsuit or just seeking information, The Gross Law Firm stands ready to assist and guide you through your rights as a shareholder of Inovio Pharmaceuticals.

Contact details, including the firm’s address and email, are readily available for anyone interested in understanding how this legal action could affect them and their investments.